Johnson & Johnson (JNJ) stock price, chart and research
Johnson & Johnson (JNJ) last traded at $282.11 at the close on November 9, 2026, up $5.89 (2.13%) on the day. In after-hours trading it was $282.65.
- Day range: $276.20 to $282.73
- 52-week range: $185.12 to $282.73
- Market cap: $679.13 billion
- P/E (trailing 12 months): 42.81
- Forward P/E: 24.27
- EPS (trailing 12 months): $6.59
- Dividend yield: 1.94%
- Volume: 6,898,091 shares
About Johnson & Johnson
Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United States; CEO: Mr. Joaquin Duato; 138,200 employees; listed since 1962-01-02.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and…
Financials
Revenue over the last 12 months was $99.33 billion, net income $16.09 billion, a profit margin of 16.2%. Revenue grew 7.8% from a year earlier.
Next earnings report: January 26, 2027.
Institutional owners of JNJ (13F)
Tracked managers holding JNJ in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $3.97 billion, 0.72% of its portfolio (reduced)
- Simplex Trading, LLC: $8.8 million, 0.28% of its portfolio (added)
- Wolverine Asset Management LLC: $468,000.00, 0.02% of its portfolio (new)
- IMC-Chicago, LLC: $301,000.00, 0.00% of its portfolio (new)
ETFs that hold JNJ
- SPY: SPDR S&P 500 ETF
- XLV: Health Care Select Sector SPDR
- VOO: Vanguard S&P 500 ETF
- IVV: iShares Core S&P 500 ETF
- VTI: Vanguard Total Stock Market
- DIA: SPDR Dow Jones Industrial
- ITOT: iShares Core S&P Total US
Research JNJ with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about JNJ: AI answers that cite dated data; no account needed for 5 prompts
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
Data: Yahoo Finance via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.